- Home
- ASC vs IGMS Comparison
ASC vs IGMS Comparison
Compare ASC & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- IGMS
- Stock Information
- Founded
- ASC 2010
- IGMS 1993
- Country
- ASC Bermuda
- IGMS United States
- Employees
- ASC N/A
- IGMS N/A
- Industry
- ASC Marine Transportation
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- IGMS Health Care
- Exchange
- ASC Nasdaq
- IGMS Nasdaq
- Market Cap
- ASC 511.3M
- IGMS 528.6M
- IPO Year
- ASC 2013
- IGMS 2019
- Fundamental
- Price
- ASC $11.29
- IGMS $7.37
- Analyst Decision
- ASC Buy
- IGMS Buy
- Analyst Count
- ASC 3
- IGMS 8
- Target Price
- ASC $20.00
- IGMS $16.25
- AVG Volume (30 Days)
- ASC 1.0M
- IGMS 213.0K
- Earning Date
- ASC 11-06-2024
- IGMS 11-08-2024
- Dividend Yield
- ASC 9.63%
- IGMS N/A
- EPS Growth
- ASC 6.23
- IGMS N/A
- EPS
- ASC 3.55
- IGMS N/A
- Revenue
- ASC $422,624,000.00
- IGMS $2,918,000.00
- Revenue This Year
- ASC N/A
- IGMS $386.95
- Revenue Next Year
- ASC N/A
- IGMS N/A
- P/E Ratio
- ASC $3.12
- IGMS N/A
- Revenue Growth
- ASC N/A
- IGMS 57.64
- 52 Week Low
- ASC $10.86
- IGMS $6.17
- 52 Week High
- ASC $23.44
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ASC 42.16
- IGMS 31.53
- Support Level
- ASC $10.87
- IGMS $7.00
- Resistance Level
- ASC $12.10
- IGMS $10.80
- Average True Range (ATR)
- ASC 0.37
- IGMS 0.96
- MACD
- ASC 0.14
- IGMS -0.10
- Stochastic Oscillator
- ASC 54.84
- IGMS 8.33
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.